PREDICT-Meso Research Tissue Bank (RTB)

• Research type

  Research Tissue Bank

• IRAS ID

  364329

• Research summary

  PREDICT-Meso (PRE-malignant Drivers Combined with Target-Drug validation in Mesothelioma) Research Tissue Bank (RTB)

• REC name

  West of Scotland REC 4

• REC reference

  26/WS/0003

• Date of REC Opinion

  15 Jan 2026

• REC opinion

  Favourable Opinion

• Data collection arrangements

  Tumour samples, other materials and data from patients are needed to develop new treatments for mesothelioma. At present, these are stored in a large number of local pathology labs and in various tissue banks in multiple institutions. This makes effective use of this rare material difficult, slowing down progress in developing new mesothelioma treatments. The PREDICT-Meso Research Tissue Bank will collate and store these valuable samples and data at one site, coordinating access for world-leading research teams. The tissues and data stored will include biopsies of benign pleural inflammation, paired with biopsies of mesothelioma that subsequently develops in the same patient.
  These ‘paired’ tissue biopsies will be supplemented by samples of blood and pleural fluid, associated with clinical information regarding each. The samples will be stored in the NHS Greater Glasgow & Clyde Biorepository, based on the Queen Elizabeth University Hospital campus in Glasgow. Patients will be able to provide written consent to their involvement by a variety of routes. Archived samples will also be retrieved and used for research where this is sufficient extra material for research purposes and current regulations allow, with the support of local pathology labs and other biorepositories and Tissue Collection Centres.

• Research programme

  The PREDICT-Meso Research Tissue Bank (RTB) supports tissue and data sharing for the PREDICT-Meso International Accelerator Network, funded by Cancer Research UK. The Network is made up of expert mesothelioma researchers from across the world. The aim of the Network is to understand how mesothelioma develops after decades of benign pleural inflammation and to design new effective therapies. A key requirement for this effort is collection of paired samples from patients with benign pleural inflammation that subsequently evolves into pleural mesothelioma during clinical follow-up. These samples will be analysed using state-of-the-art laboratory techniques to understand the processes that drive mesothelioma; to build new models of disease; and to test new treatments. The PREDICT-Meso RTB will share samples and data widely, ensuring benefits for patients are realised as quickly as possible. The Network includes founding members in the UK, Spain, Italy and Belgium, and has an expanding number of new global partners across 17 countries. Collaborators may be publicly, charitably or commercially funded, and applications for samples and data will only be considered if the PREDICT-Meso RTB is satisfied that appropriate governance and regulatory standards are in place, and that the research proposed will ultimately benefit patients.

• RTBTitle

  PREDICT-Meso (PRE-malignant Drivers Combined with Target-Drug validation in Mesothelioma) Research Tissue Bank (RTB)

• Establishment organisation

  NHS Greater Glasgow and Clyde Biorepository

• Establishment organisation address

  L3/B/012 Laboratory Medicine Building

  Queen Elizabeth University Hospital

  1345 Govan Road

  G51 4TF